NIH Study Maps How GLP-1 Drugs Like Ozempic Act on Specific Brain Cells
Similar Articles
Significant Weight Loss from GLP-1 Drugs Linked to Lower Risk of Chronic Conditions
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
Study Finds Weight Loss via GLP-1 Medications Attracts More Stigma Than Diet and Exercise
Study Analyzes Online Reports of Side Effects from Weight-Loss Medications
Study Links Wegovy to Higher Reported Risk of Rare Eye Condition
Researchers at the National Institutes of Health (NIH) have identified the specific cellular pathway through which GLP-1 weight loss drugs like semaglutide affect brain cells. The study in mice shows the drug's impact depends on increased levels of a signaling molecule called cyclic adenosine monophosphate (cAMP) in a brain region that regulates appetite. The response varied across different neurons, suggesting a more complex mechanism than previously understood.
Facts First
- GLP-1 drugs' weight loss effects depend on cAMP in the brain's appetite-regulating area postrema.
- The cAMP response varied across neurons, with some maintaining it longer than others.
- Blocking an enzyme that breaks down cAMP shifted more neurons toward a longer-lasting response.
- The research was conducted on living mouse brain tissue using fluorescence imaging.
- Some cells may reduce their response by internalizing or breaking down GLP-1 receptors.
What Happened
Researchers at the National Institutes of Health (NIH) conducted experiments on living mouse brain tissue to study how GLP-1 receptor agonists like semaglutide (found in Ozempic and Wegovy) affect neurons. The research team, led by Claire Gao, Ph.D., used fluorescence imaging to monitor the drug's effects. They found that semaglutide's impact depends heavily on increased levels of a signaling molecule called cyclic adenosine monophosphate (cAMP) in the area postrema, a brain region involved in appetite regulation. The cAMP response varied across different neurons, with some maintaining elevated levels longer than others. The team also tested blocking an enzyme called PDE4, which breaks down cAMP, and found it shifted more neurons toward a longer-lasting response.
Why this Matters to You
This research moves science closer to understanding exactly how popular weight-loss medications work in the brain at a cellular level. For anyone using or considering these drugs, a deeper understanding of their mechanism could lead to more targeted and effective future treatments with potentially fewer side effects. The finding that the response varies across neurons suggests why individual reactions to the medication might differ, which could one day help doctors personalize treatment.
What's Next
The study's limitation was that researchers could only observe intracellular signaling in brain tissue for a few hours. Further research is likely needed to understand how these short-term cellular observations translate to long-term weight loss in living animals and, eventually, humans. The identification of specific pathways, like the role of cAMP and PDE4, may open new avenues for developing next-generation therapies that more precisely target appetite regulation.